[go: up one dir, main page]

MX2007004372A - Indazoles, benzisoxazoles y benzisotiazoles y su uso como agentes estrogenicos. - Google Patents

Indazoles, benzisoxazoles y benzisotiazoles y su uso como agentes estrogenicos.

Info

Publication number
MX2007004372A
MX2007004372A MX2007004372A MX2007004372A MX2007004372A MX 2007004372 A MX2007004372 A MX 2007004372A MX 2007004372 A MX2007004372 A MX 2007004372A MX 2007004372 A MX2007004372 A MX 2007004372A MX 2007004372 A MX2007004372 A MX 2007004372A
Authority
MX
Mexico
Prior art keywords
benzisoxazoles
benzisothiazoles
indazoles
estrogenic agents
estrogenic
Prior art date
Application number
MX2007004372A
Other languages
English (en)
Inventor
Paule Bonnet
Jean Lafay
Thierry Clerc
Jacqueline Shields
Igor Duc
Eric Duranti
Christian Blot
Philippe Maillos
Benoit Rondot
Francois Puccio
Original Assignee
Theramex
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theramex filed Critical Theramex
Publication of MX2007004372A publication Critical patent/MX2007004372A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion se refiere a compuestos de la formula (1) (ver formula) en donde R1, R2, R3, X, ''Y" y A son como se definio en las especificaciones. Los compuestos son moduladores de los receptores de estrogeno.
MX2007004372A 2004-10-14 2005-10-14 Indazoles, benzisoxazoles y benzisotiazoles y su uso como agentes estrogenicos. MX2007004372A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04292439A EP1647549A1 (en) 2004-10-14 2004-10-14 Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents
PCT/EP2005/055262 WO2006040351A1 (en) 2004-10-14 2005-10-14 Indazoles, benzisoxazoles and benzisothiazoles and their use as estrogenic agents

Publications (1)

Publication Number Publication Date
MX2007004372A true MX2007004372A (es) 2007-06-07

Family

ID=34931452

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007004372A MX2007004372A (es) 2004-10-14 2005-10-14 Indazoles, benzisoxazoles y benzisotiazoles y su uso como agentes estrogenicos.

Country Status (24)

Country Link
US (2) US7977364B2 (es)
EP (2) EP1647549A1 (es)
JP (1) JP5047801B2 (es)
KR (1) KR20070109976A (es)
CN (1) CN101080395B (es)
AP (1) AP2007003960A0 (es)
AR (1) AR051457A1 (es)
AT (1) ATE512952T1 (es)
AU (1) AU2005293509B2 (es)
BR (1) BRPI0516851A (es)
CA (1) CA2582180C (es)
ES (1) ES2368203T3 (es)
IL (1) IL182047A (es)
MA (1) MA28928B1 (es)
MX (1) MX2007004372A (es)
NO (1) NO20071922L (es)
NZ (1) NZ554279A (es)
RU (1) RU2402536C2 (es)
SG (1) SG158886A1 (es)
TN (1) TNSN07138A1 (es)
TW (1) TW200619202A (es)
UA (1) UA90280C2 (es)
WO (1) WO2006040351A1 (es)
ZA (1) ZA200702690B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1647549A1 (en) * 2004-10-14 2006-04-19 Laboratoire Theramex Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents
JP4965270B2 (ja) * 2007-01-16 2012-07-04 出光興産株式会社 アダマンチルカルボニル基含有芳香族ジオール、その誘導体及びそれらの製造方法
FR2913019A1 (fr) * 2007-02-23 2008-08-29 Cerep Sa Composes heterocycliques comme agents anti-neoplasiques ou inhibiteurs de proliferation cellulaire
GB0704407D0 (en) 2007-03-07 2007-04-18 Glaxo Group Ltd Compounds
GB0803017D0 (en) 2008-02-19 2008-03-26 Glaxo Group Ltd Compounds
JP6068451B2 (ja) * 2011-05-17 2017-01-25 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・カリフオルニア キナーゼ阻害剤
US20150018398A1 (en) * 2013-07-15 2015-01-15 The Regents Of The University Of California Methods of using estrogen receptor-beta ligands as radiation mitigators
DE102015012050A1 (de) * 2015-09-15 2017-03-16 Merck Patent Gmbh Verbindungen als ASIC-Inhibitoren und deren Verwendungen
CN109111407A (zh) * 2017-06-23 2019-01-01 江苏恩华药业股份有限公司 一种苯并异恶唑类化合物衍生物及其应用
TW201920150A (zh) 2017-08-01 2019-06-01 美商施萬生物製藥研發 Ip有限責任公司 作為jak激酶抑制劑之吡唑并及三唑并雙環化合物
CN110117278B (zh) * 2018-02-07 2022-07-19 石家庄以岭药业股份有限公司 烷氧基苯并五元(六元)杂环胺类化合物及其药物用途
EP3914348A1 (en) 2019-01-23 2021-12-01 Theravance Biopharma R&D IP, LLC Imidazo[1,5-a]pyridine, 1,2,4-triazolo[4,3-a]pyridine and imidazo[1,5-a]pyrazine as jak inhibitors

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1406882A (en) * 1972-04-28 1975-09-17 Leo Pharm Prod Ltd Benzoic acid derivatives and benzisptjoaup'e 1.1 dopxode derovatoves
JPS50157363A (es) * 1974-06-06 1975-12-19
US4166452A (en) * 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) * 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) * 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US6090836A (en) * 1996-02-02 2000-07-18 Merck & Co., Inc. Benzisoxazole-derived antidiabetic compounds
DE69720429T9 (de) * 1996-02-02 2004-09-23 Merck & Co., Inc. Heterocyclische verbindungen als antidiabetische mittel und für die behandlung von fettleibigkeit
IL126745A (en) * 1997-11-04 2003-09-17 Pfizer Prod Inc Methods of preparing 4-cyano-4- (substituted indazole) cyclohexanecarboxylic acids useful as pde4 inhibitors
US6008237A (en) * 1997-12-19 1999-12-28 Merck & Co., Inc. Arylthiazolidinedione derivatives
EP1194146B1 (en) * 1999-06-18 2006-07-19 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
GB0002666D0 (en) * 2000-02-04 2000-03-29 Univ London Blockade of voltage dependent sodium channels
JP2001288175A (ja) * 2000-04-06 2001-10-16 Nippon Soda Co Ltd ヒドロキシベンゾイソオキサゾール化合物、製造方法、製造中間体、抗真菌薬および農園芸用殺菌剤
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
DE10046029A1 (de) * 2000-09-18 2002-03-28 Bayer Ag Indazole
MXPA03003845A (es) * 2000-11-02 2003-07-28 Hoffmann La Roche Benzo'b! tiofenos y benzo'd! isotiazoles bajos en colesterol.
US6608409B2 (en) * 2001-05-15 2003-08-19 General Electric Company High temperature super-conducting rotor having a vacuum vessel and electromagnetic shield and an assembly method
EP1392658A4 (en) * 2001-06-01 2004-10-13 Alcon Inc NOVEL FUSED INDAZOLES AND INDOLES AND THEIR USE IN THE TREATMENT OF GLAUCOMES
JPWO2002100833A1 (ja) 2001-06-12 2004-09-24 住友製薬株式会社 Ｒｈｏキナーゼ阻害剤
EA007430B1 (ru) * 2001-09-26 2006-10-27 Фармация Италия С.П.А. Производные аминоиндазола, активные в качестве ингибиторов киназ, способ их получения и содержащая их фармацевтическая композиция
US6960607B2 (en) * 2001-12-13 2005-11-01 Wyeth Naphthyl benzoxazoles and benzisoxazoles as estrogenic agents
US6884814B2 (en) * 2001-12-13 2005-04-26 Wyeth Phenyl benzisoxazoles as estrogenic agents
US7104676B2 (en) * 2002-04-15 2006-09-12 K.W. Muth Company, Inc. Signaling assembly
IL164209A0 (en) * 2002-05-31 2005-12-18 Eisai Co Ltd Pyrazole derivatives and pharmaceutical compositions containing the same
TW200400177A (en) * 2002-06-04 2004-01-01 Wyeth Corp 1-(Aminoalkyl)-3-sulfonylindole and-indazole derivatives as 5-hydroxytryptamine-6 ligands
TW200401641A (en) * 2002-07-18 2004-02-01 Wyeth Corp 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands
BR0314098A (pt) * 2002-09-05 2005-07-19 Aventis Pharma Sa Derivados da aminoindazóis a tìtulo de medicamentos e composições farmacêuticas que os contêm
TW200409759A (en) * 2002-09-25 2004-06-16 Wyeth Corp Substituted 4-(indazol-3-yl)phenols
CA2505127A1 (en) 2002-11-08 2004-05-27 James B. Doherty Ophthalmic compositions for treating ocular hypertension
US7196082B2 (en) * 2002-11-08 2007-03-27 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
MXPA05005554A (es) * 2002-12-12 2005-07-26 Aventis Pharma Sa Derivados de aminoindazol y su utilizacion como inhibidores de quinasas.
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
JP4617299B2 (ja) * 2003-03-03 2011-01-19 アレイ バイオファーマ、インコーポレイテッド ｐ３８阻害剤及びその使用法
US7592494B2 (en) * 2003-07-25 2009-09-22 Honeywell International Inc. Process for the manufacture of 1,3,3,3-tetrafluoropropene
DE10339719A1 (de) * 2003-08-28 2005-03-24 BSH Bosch und Siemens Hausgeräte GmbH Blähkörper zum Trocknen und/oder Glätten von Kleidungsstücken
FR2864084B1 (fr) 2003-12-17 2006-02-10 Aventis Pharma Sa Nouveaux derives organophosphores des indazoles et leur utilisation comme medicaments
WO2005085206A1 (en) * 2004-02-27 2005-09-15 F. Hoffmann-La Roche Ag Indazole derivatives and pharmaceutical compositions containing them
WO2006010595A1 (en) * 2004-07-27 2006-02-02 Novartis Ag Inhibitors of hsp90
EP1647549A1 (en) * 2004-10-14 2006-04-19 Laboratoire Theramex Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents

Also Published As

Publication number Publication date
AU2005293509A1 (en) 2006-04-20
IL182047A0 (en) 2007-07-24
ATE512952T1 (de) 2011-07-15
AR051457A1 (es) 2007-01-17
EP1812404A1 (en) 2007-08-01
NO20071922L (no) 2007-07-06
US7977364B2 (en) 2011-07-12
CA2582180C (en) 2013-04-30
AP2007003960A0 (en) 2007-04-30
CN101080395A (zh) 2007-11-28
AU2005293509B2 (en) 2012-01-12
US20090023779A1 (en) 2009-01-22
US20110237624A1 (en) 2011-09-29
JP5047801B2 (ja) 2012-10-10
TNSN07138A1 (en) 2008-11-21
EP1812404B1 (en) 2011-06-15
KR20070109976A (ko) 2007-11-15
MA28928B1 (fr) 2007-10-01
RU2402536C2 (ru) 2010-10-27
UA90280C2 (ru) 2010-04-26
WO2006040351A1 (en) 2006-04-20
CA2582180A1 (en) 2006-04-20
SG158886A1 (en) 2010-02-26
CN101080395B (zh) 2011-08-17
EP1647549A1 (en) 2006-04-19
ZA200702690B (en) 2008-10-29
BRPI0516851A (pt) 2008-09-23
ES2368203T3 (es) 2011-11-15
IL182047A (en) 2013-03-24
NZ554279A (en) 2010-09-30
TW200619202A (en) 2006-06-16
RU2007117714A (ru) 2008-11-20
US8173679B2 (en) 2012-05-08
JP2008516929A (ja) 2008-05-22

Similar Documents

Publication Publication Date Title
TNSN07138A1 (en) Indazoles, benzisoxazoles and benzisothiazoles and their use as estrogenic agents
MXPA06001592A (es) Derivados de (4-hidroxifenil)-1h-indol-3-carbaldehido oxima como agentes estrogenicos.
MX2009005462A (es) Analogos de 7,8-saturados-4,5-epoxi-morfinano.
MXPA05011597A (es) Derivados de aminopropanol como moduladores del receptor 1-fosfato de esfingosina.
MY155317A (en) Benzene sulfonamide thiazole and oxazole compounds
WO2006025979A3 (en) Modulators of nuclear receptors
MX2009005048A (es) Nuevo proceso para la preparacion de derivados de 2-imino-tiazolidin-4-ona.
TW200745067A (en) Novel compounds
MX2009003227A (es) Moduladores de los receptores de glutamato metabotropicos 5(mglur5).
MX2009010363A (es) Compuestos de 1,3-tiazol-2(3h)-ilideno como ligandos del receptor canabinoide.
MXPA05013348A (es) Derivados de amino-propanol como moduladores del receptor de esfingosina-1-fosfato.
PT2280706E (pt) Composições compreendendo derivados de benzeno que activam lipase de lipoproteína
IL181236A0 (en) Prodrug substituted benzoxazoles as estrogenic agents
ATE399775T1 (de) Triphenylethyleneverbindungen als selektive modulatoren des östrogenrezeptors
WO2008019030A3 (en) Modified azole compounds as antiinfective agents
EP1617806A4 (en) SELECTIVE SPIROCYCLIC GLUCOCORTICOID RECEPTOR MODULATORS
AR045668A1 (es) Mezcla de agentes tensioactivos y solventes
MXPA05010651A (es) Compuestos de pirazol.
WO2007118226A3 (en) Anthracenedione compounds
TW200740781A (en) Novel compounds
ZA200700739B (en) 5-lodotetrazoles
MXPA05010650A (es) Pirazoles sustituidos.
TW200744612A (en) New combination
AR046843A1 (es) Carboxamidas sililadas
TW200613315A (en) Estradiol prodrugs

Legal Events

Date Code Title Description
FG Grant or registration